• Not tested for statistical significance
  • At the time of analysis, the overall survival data were immature. The rates of death per arm and hazard ratio were unstable and do not reflect the actual OS benefit
  • The median follow-up for OS was 36 months (range: 0 to 48.6 months) 7,11
  • The rates of death were 11% (n=22) in the VEN+R arm and 20% (n=39) in the BR arm
  • The estimated 36-month OS rates were 88% (95% CI: 83-93) in the VEN+R arm and 80% (95% CI: 73-86) in the BR arm 7,11